Gestational diabetes (GDM) is a condition in which a woman without diabetes develops high blood sugar levels during pregnancy. It is characterized by the inability of pancreatic β-cells to respond adequately to the increased insulin requirements of pregnancy. As a dedicated CRO company, Ace Therapeutics offers a full range of services related to gestational diabetes, in order to help you make progress on the discovery of new or modified medications, insulin alternatives or other therapies.
Gestational diabetes (GDM) is a condition in which a woman without diabetes develops high blood sugar levels during pregnancy. In most cases, this hyperglycemia is the result of impaired glucose tolerance due to pancreatic β-cell dysfunction on a background of chronic insulin resistance. Gestational diabetes can increase the risk of preeclampsia, depression, and of needing a caesarean section.
Gestational diabetes can occur during pregnancy because of insulin resistance or reduced production of insulin. The factors include being overweight, previously having gestational diabetes, a family history of type 2 diabetes, and having polycystic ovarian syndrome. Key drivers for the increase in GDM prevalence include the obesity epidemic, physical inactivity, and rising maternal age.
The precise mechanisms underlying gestational diabetes remain unknown. The hallmark of GDM is increased insulin resistance. Pregnancy hormones (such as placental hormones, cortisol and progesterone, human placental lactogen, prolactin and estradiol, etc.) and other factors are thought to interfere with the action of insulin as it binds to the insulin receptor. The interference probably occurs at the level of the cell signaling pathway beyond the insulin receptor.
Maintaining a healthy weight and exercising before pregnancy can help prevent GDM. If diabetes diet or exercise is insufficient to control blood sugar levels, treatment with oral drugs or insulin injections may be required. Insulin, insulin analogues, and oral agents (metformin and glibenclamide) are the mainly therapies for GDM. The safety of other oral hypoglycemic agents that can be used for type 2 diabetes needs to be verified.
Pathogenesis of T1DM (Katsarou, A., et al. 2017)
Diabetes is a field worthy of in-depth research, and experts and scholars in the field of diabetes have never stopped pursuing technological innovation. Ace Therapeutics provides research programs and technical services from pathology to preclinical. Our services include but not limited to the followings.
Providing research services to study the relationship of pregnancy hormones and insulin receptor, cell signaling pathways related to gestational diabetes mellitus.
Providing modeling service for GDM study for understanding the mechanism and development of GDM, as well as developing therapy and diagnosis for GDM.
Providing a full set of services including oral antidiabetics development and safety validation service for gestational diabetes.
Providing inflammatory and adipokine biomarkers development, metabolomics and circulating biomarkers development, etc.
We provide effective diagnostics development service based on different types of markers, that can help clients complete their disease model analysis more efficiently and help accelerate therapy development of GDM.
Highly Customizable
One-stop Services
High Quality
Professional Team
With many years of experience in translational medicine research and preclinical research. Ace Therapeutics can provide our clients with treatment development solutions, and accelerate the process of treatment development and drug discovery about gestational diabetes. We guarantee to deliver our products and results on time. Please feel free to contact us.
